Platelets and Metastasis In Mice and in Humans, Platelets are Important Mediators of Metastatic process Gabriel Gasic, Tatiana Gasic, Carleton Stewart.

Slides:



Advertisements
Similar presentations
Pathogenesis of Antiphospholipid Antibodies in Pregnancy.
Advertisements

John A. Barrett Ph.D. Ziopharm Oncology, Boston MA 02129
Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.
Blood Groups and Clotting DN8 Viv Rolfe. Summary Blood transfusion –History of transfusions and what they are used for. –ABO blood group system. –Rhesus.
KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.
Antiplatelet Drugs (Anti-thrombotics)
Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.
Ch-14 Blood.
Blood July 15; 106(2): 572–576. Role of molecular mimicry to HIV-1 peptides in HIV-1–related immunologic thrombocytopenia Zongdong Li, Michael A.
Study Guide Guide for Patients Undergoing Anticoagulant Therapy.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Venous Thromboembolism
Annual prostate cancer symposium February 23, 2013 The Kimmel Cancer Center, Philadelphia, PA 2nd “ Novel Therapeutic Strategies for Prostate Cancer ”
”Cell Adhesion in Tumor Growth, Progression and Angiogenesis"
Angiogenesis ↓ Metastasis. Angiogenesis--- The process of developing new blood vessels. Cancer cells (probably like all tissues) secrete substances that.
SC121 Unit Three Karma Pace, MS AIM: kpacemcduffy.
Dies ist nur ein Beispielbild! Marcin Cebula
Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR-TKI) in Non-Small Cell Lung Cancer (NSCLC) Victor.
Obesity and Venous Thromboembolic Disease Angel Galvez MD PhD Oncology Specialists SC Lutheran General Hospital.
Pavel Yarmolenko Biology 169, Spring 2005 The von Hippel-Lindau (VHL) Tumor Suppressor Gene Inactivation and Its Involvement in Tumorgenesis.
The Use of Anti-angiogenic Factors in the Treatment of Oncologic Disease Kyle Treesh, PA-S Bob Hadley, Ph.D., PA-C, Advisor University of Kentucky.
ANTIPLATELET DRUGS.
Potential therapeutic target & predictive biomarker Oncogenic IGFBP2 Sonya Song ( 宋韦 ) Beijing Shijitan Hospital Department of Oncology The Capital Medical.
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Integrating Cells into Tissues
1. Epithelial Mesenchymal Transition ( EMT ) 2 3.
HOMING Ewing vs Paget Trapping vs homing (controlled arrest) “Seed and soil” Organ-specific metastatic colonization of favorable microenvironment.
Agents Affecting Blood Clotting
A.P. BiologyMr. Tesoro Dec. 10, 2015 Homework Reminder: Due Fri., Dec, 11, 2015 Read pages and Answer Ch. 9 Objectives (1,4,12,14)
Fibroblast Growth Factors (FGFs)
Progress in Cancer Therapy Following Developments in Biopharma
Date of download: 6/3/2016 Copyright © American College of Chest Physicians. All rights reserved. Tissue Factor, Thrombin, and Cancer * Chest. 2003;124(3_suppl):58S-68S.
Integrin-EGFR Cross-Activation Elizabeth Brooks Department of Chemical Engineering University of Massachusetts, Amherst Peyton Lab Group Meeting December.
Blood Clotting In the absence of blood vessel damage, platelets are repelled from each other and from the endothelium of blood vessels. When a blood vessel.
The role of regulatory B cells on hepatocellular carcinoma progression Conclusion Results Fig2. (A and B) In vivo, Bregs in SCID mice increased the size.
01/22/2010 – 7:45pmeSlide – P6617 – MedImmune 4 x 8 Poster Template Detection of a human anti-PDGFR  therapeutic antibody in a human GBM orthotopic rat.
Coagulation ICU – RLH Mike Cunningham 11 th December 2008.
Samsung Genome Institute Samsung Medical Center
Abstract PI3K–Akt signaling is critical for the development, progression, and metastasis of malignant tumors, but its role in the tumor microenvironment.
Epithelial-to-Mesenchymal Transitions Circulating Tumor Cells
iRGD, a tumor-penetrating peptide for tumor-specific drug delivery
Anti-Coagulants Physical Process of Clotting
Metastasis Models Folder Title: MetModels(NoTP)
Activating Invasion and Metastasis
Activating Invasion and Metastasis
Von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans by Alexander T. Bauer, Jan Suckau,
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis
The Hematologic System as a Marker of Organ Dysfunction in Sepsis
Figure 1 Mechanism of thrombus formation during ST-segment
Cells into Tissues By Kevin Huyen.
A humanized single-chain antibody against beta 3 integrin inhibits pulmonary metastasis by preferentially fragmenting activated platelets in the tumor.
HOMING
Figure 4 Tumour-induced neutrophil extracellular trap
Figure 4 Macrophage-targeting antitumour treatment approaches
Volume 56, Issue 4, Pages (October 1999)
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Volume 5, Issue 5, Pages (December 2013)
TGF-β Receptor I/ ALK-5 and Pancreatic and Biliary Cancer
Heather L Maecker, Zhong Yun, Holden T Maecker, Amato J Giaccia 
Tumor-Associated Macrophages: From Mechanisms to Therapy
Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.
Trousseau's syndrome: multiple definitions and multiple mechanisms
Multiple mechanisms in Trousseau's syndrome.
Experimental metastasis inhibition by primary tumors is mediated by NK cells and IFNγ. Experimental metastasis inhibition by primary tumors is mediated.
The Role of TIPE2 Protein in Invasive Breast Carcinoma
Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.
Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.
Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.
Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.
Presentation transcript:

Platelets and Metastasis In Mice and in Humans, Platelets are Important Mediators of Metastatic process Gabriel Gasic, Tatiana Gasic, Carleton Stewart PNAS 61:46-52, 1968

Transfusion of Platelet Rich Plasma Reverses Neuraminidase Effect on Metastasis

Treatment of Mice with Anti-Platelet Serum Produces the Same Effect as Neuraminidase

How do platelets contribute to metastasis?  In many cancer patients platelet numbers are elevated.  Platelets in cancer patients are activated (elevated levels of serum thrombin, von Willebrand factor, VEGF).  Prostacyclin/Thromboxane A2 balance disturbed in many cancer patients.  Hypercoagulable state of blood in many cancer patients  Heparin (an anti-coagulant) protected against pulmonary metastasis in animal models Hypotheis 1. Activation of clotting pathway.

However, Clinical trials that used anti-coagulants (vitamin K antagonists such as warfarin) failed. And yet…. Retrospective analysis indicated that cancer patients that were treated with low doses of heparin before cancer surgery showed improved survival. Cancer patients treated with heparin to combat venous thromboemolism also showed improved survival.

Activated platelets secrete cytokynes such as VEGF A, PDGF, TGF , bFGF that promote Tumor growth and angiogenesis. Cancer patients undergoing chemotherapy experience decrease in platelet counts (thrombosytopenia) and receive platelet transfusion. BUT platelets become activated during storage (secrete P-selectin and VEGF). Transfusion of blood products carries the risk of increased cancer recurrence. Nash et al., Platelets and Cancer. Lancet Oncology 3:425, 2002

Hypotheis 2. Platelets interact directly with tumor cells, and this interaction facilitates metastasis. Two modes of interaction Platelets interact with tumor cells via Integrins (  IIb  3), vWF, fibronectin, fibrinogen P-selectin on platelets binds to tumor cell carbohydrate coat (sialyl Lewis a/x ) Coating of tumor cells by platelets protects tumor cells from killing by immune cells, shear forces, allows them to attach, extravasate, grow and recruit blood vessels

Selectins: ELPELP

Sialyl Lewis A Sialyl Lewis X

sulfatides Selectin Ligands

Tumor cells upregulate sLa/x Progression to invasive phenotype of tumor cells in vitro and tumors in vivo is associated with upregulation of cell surface sLa/x Upregulation of sLa/x is a poor prognostic factor for colon, pancreas and stomach cancers Expression of sLa on colon adenocarcinomas correlates with appearance liver metastasis sLa/x on mucin-type O-glycans is highly correlated with lymphatic and venous metastasis Ugorski et al., Acta Biochimica Polonica 49: , 2002

Experimental Mouse Models: Treatment of tumor cells with O-sialglycosidase (cleaves glycosylated mucins) inhibits tumor mets Treatment of tumor cells with monoclonal Ab to sLa inhibits tumor mets Heparin actually competes with sLa/x for binding to selectins also inhibits tumor mets However, Experiments in mice also showed that levels of sLa/x are important. When too much of sLa/x are present on tumor cell surface (presentation of sLa/x is altered), tumor cells are subject to attack by NK cells. Ohyama et al., EMBO J., 18: , 1999

Selectin Kos Experimental pulmonary mets are attenuated in P-KO mice. Kim et al, PNAS 95:9325, 1998

3-D Reconstruction of Tumor-Platelet-Leukocyte Emboli in Blood Vessels of the Lung Borsig et al (Varki) PNAS 98:3352, 2001 Tumor Cells Platelets Leukocytes

Heparin does not equal Heparin 1.Low MW Heparin fraction does not have the same effect 2.Heparin fragments generated by different heparinases exhibit different effects on tumor growth and metastasis. Fragments resulting from digestion of tumor cell surface with HepIII inhibit tumor growth and metastasis. But fragments resulting from digestion with HepI promote tumor growth! Liu et al, PNAS 99: , 2002

Hypotheis 2. Platelets interact directly with tumor cells, and this interaction facilitates metastasis. Two modes of interaction Platelets interact with tumor cells via Integrins (  IIb  3), vWF, fibronectin, fibrinogen P-selectin on platelets binds to tumor cell carbohydrate coat (sialyl Lewis a/x ) Coating of tumor cells by platelets protects tumor cells from killing by immune cells, shear forces, allows them to attach, extravasate, grow and recruit blood vessels

Treatment of cell lines with trypsin, hrombin or antibodies to fibronectin, vWF,  IIb  3 inhibits tumor cell binding to platelets Treatment of mice with antibodies to vWF,  IIb  3, RGDS peptides, or thrombin attenuate tumor metastasis. Karpatkin et al, J. Clin. Invest 1988 Nierodzik et al, Thromb and Haemostasis 74:282, 1995

Seeding of metastasis is attenuated in the absence of Fibrinogen. Palumbo et al., Blood 96: 3302, 2000

Tumor cells disappear from the lungs in Fg -/- mice!

Targeted disruption of platelet-tumor interactions is worth clinical testing again (Varki) Heparin treatment to inhibit tumor cells association with platelets (as well as inhibiut platelet activation by thrombin) may be of great therapeutic, anti-metastatic effect Other inhibitors of platelet-tumor interactions may be helpful as well